HU-210

HU-210 is a synthetic cannabinoid that was first synthesized in 1988 from (1R,5S)-myrtenol by a group led by Raphael Mechoulam at the Hebrew University. HU-210 is 100 to 800 times more potent than natural THC from cannabis and has an extended duration of action. HU-210 is the (–)-1,1-dimethylheptyl analog of 11-hydroxy- Δ8- THC; in some references it is called 1,1-dimethylheptyl- 11-hydroxytetrahydrocannabinol. The abbreviation "HU" stands for Hebrew University.

Chemistry

HU-210 is a member of the HU-series of cannabinoids, a group of synthetic molecules that are named after the Hebrew University of Jerusalem where they were first synthesized. HU-210 is a chiral compound, meaning it has two enantiomers, one of which is biologically active.

Pharmacology

HU-210 is a potent analgesic and anti-inflammatory agent. It also has neuroprotective effects and can prevent the death of neurons in the brain. HU-210 is a full agonist at the CB1 receptor and the CB2 receptor, the two main cannabinoid receptors in the body.

Effects

The effects of HU-210 are similar to those of other cannabinoids, but much more potent. These effects include pain relief, anti-inflammation, appetite stimulation, and euphoria. However, because of its potency, the risk of psychotic side effects is also increased.

Legal status

HU-210 is illegal in many countries, including the United States, where it is classified as a Schedule I drug.

See also

• Cannabinoid
• Cannabinoid receptor
• Synthetic cannabinoids
• Raphael Mechoulam

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  HU-210 structure
• 
  HU-210 BNS